Eli Lilly has agreed to acquire eye disease specialist Adverum Biotechnologies, bucking a recent trend of big pharma ...

Chugai has signed a definitive stock agreement to purchase Japan-based Renalys Pharma, augmenting its kidney disease ...

Novartis has signed an agreement for the acquisition of all the outstanding shares of US-based Avidity Biosciences.

Zavodnick told Pharmaceutical Technology that Excellergy plans to initiate an ex-US Phase I study of its lead ECRI candidate, a monoclonal antibody, in Q1 2026, with the goal of being ready for Phase ...

The MHRA's raid follows an uptick in the trade of illegal GLP-1RA drugs used for obesity and type 2 diabetes amid shortages ...

Dupixent’s Q3 sales increased by 26.2%, breaking through the €4bn ceiling for the first time in a single quarter.

GSK has received US Food and Drug Administration (FDA) approval for Blenrep to be used along with BVd for multiple myeloma.

Immunotherapy drugs continue to gain momentum across a growing range of disease areas with blockbusters such as Merck’s ...

Roche’s CEO Thomas Schinecker said the drugmaker is continuing talks with the US government over drug pricing reforms, as ...

A report by GlobalData revealed that the biotech industry witnessed a 70.9% increase in total venture financing deal value.

Merck KGaA could now have a head start in the race to market Precem-TcT, which could become the first widely approved ADC in ...

Early-stage equity raises for biotechs surged by 71% in Q3 2025, hinting that the funding freeze that has gripped the ...